Last updated 19 days ago
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
700 patients around the world
Available in Puerto Rico, Spain, Argentina, United States, Belgium, Brazil
Incyte Corporation
24Research sites
700Patients around the world
This study is for people with
Colorectal cancer
Requirements for the patient
From 18 Years
All Gender
Medical requirements
- Stage IV colorectal adenocarcinoma not amenable to curative resection.No prior systemic treatment for unresectable or metastatic disease.Participants who received adjuvant or neoadjuvant therapy may enroll if there was no recurrence within 12 months of the end of treatment.Measurable disease per RECIST v1.1.ECOG performance status of 0 or 1.Adequate organ function determined by laboratory results.Other protocol-defined inclusion/exclusion criteria apply.
- MSI-H/dMMR per historical data in the medical record.BRAF V600E mutation per historical data in the medical record.Untreated and/or progressing CNS metastases.History of other malignancy within 2 years.Treatment with an anti-PD-(L)1 or other immune checkpoint inhibitor for any indication within the last 3 years.Active autoimmune disease that has required systemic treatment in the past 2 years.Significant concurrent and/or uncontrolled medical condition.History of organ transplant, including allogeneic stem cell transplantation.
Sites
Exelsus - Oncología Clínica - Tucumán
Instituto de Investigaciones Clínicas Córdoba
Fundación Cori para la Investigación y Prevención del Cáncer - La Rioja
Hospital Británico de Buenos Aires - CABA
Investigaciones Clínicas Moleculares - ICM
Instituto Médico Especializado Alexander Fleming - CABA, Buenos Aires
Instituto de Oncología de Rosario - IOR
Hospital Privado de Córdoba
Clínica Colón - Mar del Plata
Hospital Italiano de Buenos Aires - CABA, Buenos Aires
SponsorIncyte Corporation
Study typeInterventional
Conditions
Colorectal cancer
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT07284849
